Skip to main content
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Jan;2(1):120–121. doi: 10.1128/cdli.2.1.120-121.1995

Time to peak serum antibody response to influenza vaccine.

S Rastogi 1, P A Gross 1, J Bonelli 1, S Dran 1, R A Levandowski 1, C Russo 1, M E Weksler 1, D Kaye 1, M Levison 1, E Abrutyn 1, et al.
PMCID: PMC170112  PMID: 7719904

Abstract

The time to the appearance of a peak serum antibody response to influenza virus vaccine is not clearly defined. We compared the most commonly used time intervals described in the literature--4 and 6 weeks after vaccination. We studied 118 elderly patients from three different geographic sites. The 1992 to 1993 trivalent inactivated influenza virus vaccine containing influenza virus A/Beijing/353/89 (H3N2), influenza virus A/Texas/36/91 (H1N1), and influenza virus B/Panama/45/90 was used. No statistically significant differences were found at the 4- and 6-week intervals after vaccination.

Full Text

The Full Text of this article is available as a PDF (142.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brandriss M. W., Betts R. F., Mathur U., Douglas R. G., Jr Responses of elderly subjects to monovalent A/USSR/77 (H1N1) and Trivalent A/USSR/77 (H1N1)-A/TEXAS/77 (H3N2)-B/Hong Kong/72 vaccines. Am Rev Respir Dis. 1981 Dec;124(6):681–684. doi: 10.1164/arrd.1981.124.6.681. [DOI] [PubMed] [Google Scholar]
  2. Gross P. A., Ennis F. A., Gaerlan P. F., Denson L. J., Denning C. R., Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis. 1977 Nov;136(5):623–632. doi: 10.1093/infdis/136.5.623. [DOI] [PubMed] [Google Scholar]
  3. Gross P. A., Quinnan G. V., Rodstein M., LaMontagne J. R., Kaslow R. A., Saah A. J., Wallenstein S., Neufeld R., Denning C., Gaerlan P. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med. 1988 Mar;148(3):562–565. [PubMed] [Google Scholar]
  4. Hilleman M. R. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog Med Virol. 1966;8:131–182. [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES